Astal Laboratories Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 157295, "name": "Astal Lab", "stock_name": "Astal Lab", "full_name": "Astal Laboratories Ltd", "name_url": "stocks-analysis/astal-lab", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "71.50", "chg": 0.55, "chgp": "0.78%", "dir": 1, "prev_price": "70.95", "mcapval": "310.00 Cr", "mcap": "Micro Cap", "scripcode": 512600, "symbol": "", "ind_name": "Trading & Distributors", "ind_code": 49, "indexname": "", "isin": "INE307N01014", "curr_date": "Mar 05", "curr_time": "", "bse_nse_vol": "3.76 k", "exc_status": "Active", "traded_date": "Mar 05, 2026", "traded_date_str": "2026 03 05", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/astal-lab-157295-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Astal Laboratories Ltd Falls to 52-Week Low of Rs.70.1 Amid Market Pressure", "link": "https://www.marketsmojo.com/news/stocks-in-action/astal-laboratories-ltd-falls-to-52-week-low-of-rs701-amid-market-pressure-3864477", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AstalLaboratori_priceRelatedfactors_3864477.png", "date": "2026-03-02 11:04:11", "description": "Astal Laboratories Ltd, a player in the Trading & Distributors sector, recorded a fresh 52-week low today at Rs.70.1, marking a significant decline amid broader market fluctuations and sectoral pressures. The stock’s recent performance reflects a continuation of downward momentum, with notable implications for its valuation and comparative market standing." }, { "title": "Astal Laboratories Ltd Declines 0.42% Despite Quality Upgrade: 3 Key Factors Behind the Week’s Moves", "link": "https://www.marketsmojo.com/news/stocks-in-action/astal-laboratories-ltd-declines-042-despite-quality-upgrade-3-key-factors-behind-the-weeks-moves-3863261", "imagepath": "", "date": "2026-03-01 15:00:05", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>16 Feb:</strong> Quality grade upgraded from below average to average</p>\n <p><strong>17 Feb:</strong> Mojo Grade upgraded from Strong Sell to Sell amid strong Q3 FY26 results</p>\n <p><strong>17 Feb:</strong> Stock price rebounds sharply by 7.25% after two days of decline</p>\n <p><strong>20 Feb:</strong> Week closes at Rs.79.00, down 0.42% for the week</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.79.33</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div..." }, { "title": "Astal Laboratories Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/astal-laboratories-ltd-is-rated-sell-3862152", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AstalLaboratori_mojoScore_3862152.png", "date": "2026-02-28 10:10:03", "description": "Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Astal Laboratories Q3 FY26: Growth Momentum Masks Alarming Margin Erosion", "link": "https://www.marketsmojo.com/news/result-analysis/astal-laboratories-q3-fy26-growth-momentum-masks-alarming-margin-erosion-3844511", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AstalLaboratori_quaterlyResult_3844511.png", "date": "2026-02-17 11:32:12", "description": "Astal Laboratories Ltd., a micro-cap pharmaceutical intermediates and bulk drugs manufacturer, reported net profit of ₹2.36 crores for Q3 FY26 (October-December 2025), reflecting an 8.53% decline quarter-on-quarter but a modest 5.22% decline year-on-year. Despite impressive top-line expansion, the company's profitability metrics reveal a concerning deterioration in operational efficiency that has sent the stock into bearish territory, trading at ₹77.60 as of February 17, 2026—down 24.81% from its 52-week high of ₹103.20." }, { "title": "Astal Laboratories Ltd Upgraded to Sell on Improved Quality and Financial Trends", "link": "https://www.marketsmojo.com/news/stock-recommendation/astal-laboratories-ltd-upgraded-to-sell-on-improved-quality-and-financial-trends-3843699", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AstalLaboratori_mojoScore_3843699.png", "date": "2026-02-17 08:13:06", "description": "Astal Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting notable improvements in its quality metrics and financial trends despite valuation concerns and recent price weakness. The revised assessment follows a comprehensive review of four key parameters: Quality, Valuation, Financial Trend, and Technicals." }, { "title": "Astal Laboratories Ltd Quality Grade Upgrade: A Detailed Analysis of Business Fundamentals", "link": "https://www.marketsmojo.com/news/stocks-in-action/astal-laboratories-ltd-quality-grade-upgrade-a-detailed-analysis-of-business-fundamentals-3843102", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AstalLaboratori_qualitydot_3843102.png", "date": "2026-02-17 08:00:17", "description": "Astal Laboratories Ltd has seen its quality grade improve from below average to average, reflecting a nuanced shift in its business fundamentals. While key metrics such as return on equity (ROE) and return on capital employed (ROCE) remain modest, improvements in sales and earnings growth alongside low debt levels have contributed to this upgrade. However, investors should weigh these positives against the company’s middling profitability ratios and recent share price underperformance relative to the Sensex." }, { "title": "Are Astal Laboratories Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-astal-laboratories-ltd-latest-results-good-or-bad-3840319", "imagepath": "", "date": "2026-02-14 19:38:09", "description": "Astal Laboratories Ltd has reported significant operational changes in its latest financial results for Q2 FY26. The company achieved net sales of ₹37.52 crores, reflecting a remarkable year-on-year growth of 185.11%, indicating a strong recovery and expansion from its previous operational dormancy. This growth trajectory is notable, especially considering the company’s revenue was only ₹13.16 crores in the same quarter last year.\n\nHowever, while revenue growth is impressive, it is accompanied by a concerning trend in profitability. The net profit for the quarter stood at ₹2.58 crores, marking a 29.00% increase year-on-year. Despite this positive figure, the profit margins have faced compression, with the PAT margin declining to 6.88% from 8.25% in the previous quarter. This suggests that the aggressive pursuit of revenue growth may be impacting operational efficiency and pricing power.\n\nThe operating profi..." }, { "title": "When is the next results date for Astal Laboratories Ltd?", "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-astal-laboratories-ltd-3833739", "imagepath": "", "date": "2026-02-11 23:16:28", "description": "The next results date for Astal Laboratories Ltd is scheduled for 14 February 2026...." }, { "title": "Astal Laboratories Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/astal-laboratories-ltd-is-rated-strong-sell-3830558", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AstalLaboratori_mojoScore_3830558.png", "date": "2026-02-10 10:10:07", "description": "Astal Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook." } ], "total": 127, "sid": "157295", "stock_news_url": "https://www.marketsmojo.com/news/astal-laboratories-157295" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "16-Feb-2026", "details": "Submission of newspaper publication.", "source": "BSE" }, { "caption": "Results- Financial Results For December 31 2025.", "datetime": "14-Feb-2026", "details": "Submission of Unaudited Financial Results for the quarter ended December 31 2025.", "source": "BSE" }, { "caption": "Compliances- Statement Of Deviation & Variation", "datetime": "14-Feb-2026", "details": "Submission of Statement of Deviation & Variation.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

16 Feb: Quality grade upgraded from below average to average

17 Feb: Mojo Grade upgraded from Strong Sell to Sell amid strong Q3 FY26 results

17 Feb: Stock price rebounds sharply by 7.25% after two days of decline

20 Feb: Week closes at Rs.79.00, down 0.42% for the week

Week Open

Rs.79.33

Week CloseRead full news article

Astal Laboratories Ltd is Rated Sell

2026-02-28 10:10:03

Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Astal Laboratories Q3 FY26: Growth Momentum Masks Alarming Margin Erosion

2026-02-17 11:32:12

Astal Laboratories Ltd., a micro-cap pharmaceutical intermediates and bulk drugs manufacturer, reported net profit of ₹2.36 crores for Q3 FY26 (October-December 2025), reflecting an 8.53% decline quarter-on-quarter but a modest 5.22% decline year-on-year. Despite impressive top-line expansion, the company's profitability metrics reveal a concerning deterioration in operational efficiency that has sent the stock into bearish territory, trading at ₹77.60 as of February 17, 2026—down 24.81% from its 52-week high of ₹103.20.

Read full news article

Astal Laboratories Ltd Upgraded to Sell on Improved Quality and Financial Trends

2026-02-17 08:13:06

Astal Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting notable improvements in its quality metrics and financial trends despite valuation concerns and recent price weakness. The revised assessment follows a comprehensive review of four key parameters: Quality, Valuation, Financial Trend, and Technicals.

Read full news article

Astal Laboratories Ltd Quality Grade Upgrade: A Detailed Analysis of Business Fundamentals

2026-02-17 08:00:17

Astal Laboratories Ltd has seen its quality grade improve from below average to average, reflecting a nuanced shift in its business fundamentals. While key metrics such as return on equity (ROE) and return on capital employed (ROCE) remain modest, improvements in sales and earnings growth alongside low debt levels have contributed to this upgrade. However, investors should weigh these positives against the company’s middling profitability ratios and recent share price underperformance relative to the Sensex.

Read full news article

Are Astal Laboratories Ltd latest results good or bad?

2026-02-14 19:38:09

Astal Laboratories Ltd has reported significant operational changes in its latest financial results for Q2 FY26. The company achieved net sales of ₹37.52 crores, reflecting a remarkable year-on-year growth of 185.11%, indicating a strong recovery and expansion from its previous operational dormancy. This growth trajectory is notable, especially considering the company’s revenue was only ₹13.16 crores in the same quarter last year. However, while revenue growth is impressive, it is accompanied by a concerning trend in profitability. The net profit for the quarter stood at ₹2.58 crores, marking a 29.00% increase year-on-year. Despite this positive figure, the profit margins have faced compression, with the PAT margin declining to 6.88% from 8.25% in the previous quarter. This suggests that the aggressive pursuit of revenue growth may be impacting operational efficiency and pricing power. The operating profi...

Read full news article

When is the next results date for Astal Laboratories Ltd?

2026-02-11 23:16:28

The next results date for Astal Laboratories Ltd is scheduled for 14 February 2026....

Read full news article

Astal Laboratories Ltd is Rated Strong Sell

2026-02-10 10:10:07

Astal Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article